Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer

References

• Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130(1):107–114.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhang W, Li XG, et al. The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer. Zhonghua Zhong Liu Za Zhi. 2012;34(3):196–200.
   PubMedGoogle Scholar
• Kruh GD. Lustrous insights into cisplatin accumulation: copper transporters. Clinical Cancer Res: An Off J Am Assoc Cancer Res. 2003;9(16 Pt 1):5807–5809.
   Web of Science ®Google Scholar
• Bowden NA. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 2014;346(2):163–171.
   PubMed Web of Science ®Google Scholar
• Samimi G, Katano K, Holzer AK, et al.. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol. 2004;66(1):25–32.
   PubMed Web of Science ®Google Scholar
• Jeon YJ, Kim DH, Jung H, et al. Annexin A4 interacts with the NF-kappaB p50 subunit and modulates NF-kappaB transcriptional activity in a Ca2+-dependent manner. Cellular Mole Life Sci: CMLS. 2010;67(13):2271–2281.
   PubMed Web of Science ®Google Scholar
• Park JT, Chen X, Tropè CG, et al.. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177(3):1087–1094.
   PubMed Web of Science ®Google Scholar
• Yu Y, Gaillard S, Phillip JM, et al. Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell. 2015;28(1):82–96.
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, et al.. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22(47):7280–7295.
   PubMed Web of Science ®Google Scholar
• Roque DM, Bellone S, Buza N, et al. Class III beta-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am J Obstet Gynecol. 2013;209(1):62 e61–69.
   Web of Science ®Google Scholar
• Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006;580(4):998–1009.
   PubMed Web of Science ®Google Scholar
• Silasi DA, Alvero AB, Illuzzi J, et al. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med. 2006;79(3–4):153–163.
   PubMedGoogle Scholar
• Cheng JQ, Jiang X, Fraser M, et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updates: Rev Comment Antimicrobial Anticancer Chemother. 2002;5(3–4):131–146.
   Google Scholar
• Yang X, Fraser M, Abedini MR, et al.. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer. 2008;98(4):803–808.
   PubMed Web of Science ®Google Scholar
• Yang X, Fraser M, Moll UM, et al.. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 2006;66(6):3126–3136.
   PubMed Web of Science ®Google Scholar
• Brachova P, Mueting SR, Carlson MJ, et al. TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 2015;46(2):607–618.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–7279.
   PubMed Web of Science ®Google Scholar
• Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.
   PubMed Web of Science ®Google Scholar
• Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006;70(4):1390–1394.
   PubMed Web of Science ®Google Scholar
• Samimi G, Safaei R, Katano K, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clinical Cancer Res: An Off J Am Assoc Cancer Res. 2004;10(14):4661–4669.
   PubMed Web of Science ®Google Scholar
• Korita PV, Wakai T, Shirai Y, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep. 2010;23(4):965–972.
   PubMed Web of Science ®Google Scholar
• Zhang H, Jing X, Wu X, et al. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes. Anticancer Drugs. 2015;26(7):706–715.
   PubMed Web of Science ®Google Scholar
• Li M, Balch C, Montgomery JS, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009;2:34.
   PubMed Web of Science ®Google Scholar
• Vergote I, Finkler N, Del Campo J, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer. 2009;45(13):2324–2332.
   PubMed Web of Science ®Google Scholar
• Vergote I, Finkler NJ, Hall JB, et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2010;20(5):772–780.
   PubMed Web of Science ®Google Scholar
• Selvakumaran M, Pisarcik DA, Bao R, et al.. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63(6):1311–1316.
   PubMed Web of Science ®Google Scholar
• Dabholkar M, Vionnet J, Bostick-Bruton F, et al.. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994;94(2):703–708.
   PubMed Web of Science ®Google Scholar
• Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep. 2011;25(3):749–762.
   PubMed Web of Science ®Google Scholar
• Pink RC, Samuel P, Massa D, et al.. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143–151.
   PubMed Web of Science ®Google Scholar
• Auersperg N, Wong AS, Choi KC, et al.. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001;22(2):255–288.
   PubMed Web of Science ®Google Scholar
• Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009;69(7):2996–3003.
   PubMed Web of Science ®Google Scholar
• Spentzos D, Cannistra SA, Grall F, et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer. 2007;14(3):781–790.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Ranieri G, Basile A, et al.. Tumor endothelial markers as a target in cancer. Expert Opin Ther Targets. 2012;16(12):1215–1225.
   PubMed Web of Science ®Google Scholar
• Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193(9):1005–1014.
   PubMed Web of Science ®Google Scholar
• Schlingemann RO, Oosterwijk E, Wesseling P, et al.. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol. 1996;179(4):436–442.
   PubMed Web of Science ®Google Scholar
• Marchiò S, Lahdenranta J, Schlingemann RO, et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell. 2004;5(2):151–162.
   PubMed Web of Science ®Google Scholar
• Sato M, Arap W, Pasqualini R. Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology (Williston Park, N.Y.). 2007;21(11):1346–1352. discussion 1354–1345, 1367, 1370 passim
   PubMed Web of Science ®Google Scholar
• Hatakeyama S, Sugihara K, Shibata TK, et al. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc Natl Acad Sci U S A. 2011;108(49):19587–19592.
   PubMed Web of Science ®Google Scholar
• Koutsioumpa M, Drosou G, Mikelis C, et al. Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin. Vascular Cell. 2012;4:4.
   PubMedGoogle Scholar
• Nanda A, St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol. 2004;16(1):44–49.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502–516.
   PubMed Web of Science ®Google Scholar
• Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001;28(2 Suppl 8):36–41.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang QH, Ao QL, et al.. Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism. Zhonghua Zhong Liu Za Zhi. 2007;29(2):96–100.
   PubMedGoogle Scholar
• Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012;30(32):4026–4034.
   PubMed Web of Science ®Google Scholar
• Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updates: Rev Comment Antimicrobial Anticancer Chemother. 2011;14(3):191–201.
   Google Scholar
• Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–430.
   PubMed Web of Science ®Google Scholar
• Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12(17):5055–5063.
   PubMed Web of Science ®Google Scholar
• Kuh HJ, Jang SH, Wientjes MG, et al.. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290(2):871–880.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al.. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–234.
   PubMed Web of Science ®Google Scholar
• Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clinical Cancer Res: An Off J Am Assoc Cancer Res. 2005;11(1):298–305.
   PubMed Web of Science ®Google Scholar
• Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer. 2007;120(10):2078–2085.
   PubMed Web of Science ®Google Scholar
• Roque DM, Buza N, Glasgow M, et al. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis. 2014;31(1):101–110.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Lu Z, Jennings NB, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010;18(2):109–121.
   PubMed Web of Science ®Google Scholar
• Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clinical Cancer Res: An Off J Am Assoc Cancer Res. 2002;8(7):2246–2252.
   Web of Science ®Google Scholar
• Suh DH, Kim MK, Kim HS, et al.. Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer. Journal Cancer Prev. 2013;18(3):227–234.
   PubMedGoogle Scholar
• Kim A, Enomoto T, Serada S, et al. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer. 2009;125(10):2316–2322.
   PubMed Web of Science ®Google Scholar
• Tait JF, Smith C, Frankenberry DA, et al.. Chromosomal mapping of the human annexin IV (ANX4) gene. Genomics. 1992;12(2):313–318.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Ludwig J, Xia D, et al.. Defeating drug resistance in cancer. Discov Med. 2006;6(31):18–23.
   PubMedGoogle Scholar
• Willshaw A, Grant K, Yan J, et al. Identification of a novel protein complex containing annexin A4, rabphilin and synaptotagmin. FEBS Lett. 2004;559(1–3):13–21.
   PubMed Web of Science ®Google Scholar
• Zimmermann U, Balabanov S, Giebel J, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004;209(1):111–118.
   PubMed Web of Science ®Google Scholar
• Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Serada S, Enomoto T, et al. Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. Oncotarget. 2014;5(17):7776–7787.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116(13):3276–3284.
   PubMed Web of Science ®Google Scholar
• d’Adhemar CJ, Spillane CD, Gallagher MF, et al. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. Plos One. 2014;9(6):e100816.
   Google Scholar
• Zeromski J, Mozer-Lisewska I, Kaczmarek M. Significance of toll-like receptors expression in tumor growth and spreading: a short review. Cancer Microenviron: Offl J Int Cancer Microenviron Soc. 2008;1(1):37–42.
   PubMedGoogle Scholar
• Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8(1):158–166.
   PubMed Web of Science ®Google Scholar
• Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updates: Rev Comment Antimicrobial Anticancer Chemother. 2012;15(1–2):39–49.
   Google Scholar
• Zhu LC, Gao J, Hu ZH, et al. Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 2015;5(2):830–843.
   PubMed Web of Science ®Google Scholar
• Liu JJ, Lin B, Hao YY, et al. Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep. 2010;23(3):833–841.
   PubMed Web of Science ®Google Scholar
• Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001;61(5):1862–1868.
   PubMed Web of Science ®Google Scholar
• Dan HC, Jiang K, Coppola D, et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 2004;23(3):706–715.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang L, Yu L, et al. shRNA-mediated AMBRA1 knockdown reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin. J Toxicol Sci. 2016;41(1):45–53.
   PubMed Web of Science ®Google Scholar
• Fraser M, Leung BM, Yan X, et al.. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 2003;63(21):7081–7088.
   PubMed Web of Science ®Google Scholar
• Latifi A, Abubaker K, Castrechini N, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem. 2011;112(10):2850–2864.
   PubMed Web of Science ®Google Scholar
• Nash MA, Ferrandina G, Gordinier M, et al.. The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer. 1999;6(1):93–107.
   PubMed Web of Science ®Google Scholar
• Kumar J, Ward AC. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications. Biochim Biophys Acta. 2014;1845(2):117–125.
   PubMed Web of Science ®Google Scholar
• Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1–38.
   PubMed Web of Science ®Google Scholar
• Han Z, Feng J, Hong Z, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013;435(2):188–194.
   PubMed Web of Science ®Google Scholar
• Fraser M, Leung B, Jahani-Asl A, et al.. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol: RB&E. 2003;1:66.
   PubMedGoogle Scholar
• Watson JM, Sensintaffar JL, Berek JS, et al.. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990;50(21):6959–6965.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li L, Guo X, et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 2012;59(2):228–236.
   PubMed Web of Science ®Google Scholar
• Liu S, Liu C, Min X, et al. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. Plos One. 2013;8(11):e81050.
   Google Scholar
• Wei X, Dombkowski D, Meirelles K, et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A. 2010;107(44):18874–18879.
   PubMed Web of Science ®Google Scholar
• Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Journal International Du Cancer [Int J Cancer]. 2004;112(1):14–25.
   PubMed Web of Science ®Google Scholar
• English DP, Bellone S, Schwab CL, et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 2015;121(3):403–412.
   PubMed Web of Science ®Google Scholar
• Arabi L, Badiee A, Mosaffa F, et al.. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. J Controlled Release: Off J Controlled Release Soc. 2015;220(Pt A):275–286.
   PubMed Web of Science ®Google Scholar
• Cochrane DR, Spoelstra NS, Howe EN, et al.. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009;8(5):1055–1066.
   PubMed Web of Science ®Google Scholar
• Cittelly DM, Dimitrova I, Howe EN, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012;11(12):2556–2565.
   PubMed Web of Science ®Google Scholar
• Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis. 2013;2:e40.
   PubMed Web of Science ®Google Scholar
• Van Jaarsveld MT, Helleman J, Boersma AW, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013;32(36):4284–4293.
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425–433.
   PubMed Web of Science ®Google Scholar
• Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A. 2013;110(24):9845–9850.
   PubMed Web of Science ®Google Scholar
• Yu PN, Yan MD, Lai HC, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014;134(3):542–551.
   PubMed Web of Science ®Google Scholar
• Chen C, Hu Y, Li L. NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis. Mol Med Rep. 2016;13(1):188–196.
   PubMed Web of Science ®Google Scholar
• Gao YC, Wu J. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Tumour Biol. 2015;36(6):4843–4850.
   PubMed Web of Science ®Google Scholar
• Liu Y, Qiang W, Xu X, et al. Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget. 2015;6(36):38983–38998.
   PubMed Web of Science ®Google Scholar
• Penna E, Orso F, Taverna D. miR-214 as a key hub that controls cancer networks: small player, multiple functions. J Invest Dermatol. 2015;135(4):960–969.
   PubMed Web of Science ®Google Scholar
• Huh JH, Kim TH, Kim K, et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer. 2013;109(2):452–461.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76(5):582–588.
   PubMed Web of Science ®Google Scholar
• Sorrentino A, Liu CG, Addario A, et al.. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–486.
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Park SM, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012;130(8):1787–1797.
   PubMed Web of Science ®Google Scholar
• Liu N, Zhou C, Zhao J, et al.. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest. 2012;30(8):577–582.
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Lee SH, Jones A, et al. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med. 2015;7(1):108.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Guo J, Chen L, et al.. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. Oncotarget. 2015;6(28):25381–25389.
   PubMed Web of Science ®Google Scholar
• Rooney PH, Murray GI, Stevenson DA, et al.. Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer. 1999;80(5–6):862–873.
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim JW, Kim YT, et al. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer. 2007;46(1):1–9.
   PubMed Web of Science ®Google Scholar
• Engler DA, Gupta S, Growdon WB, et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. Plos One. 2012;7(2):e30996.
   Google Scholar
• Osterberg L, Levan K, Partheen K, et al.. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet. 2005;163(2):144–150.
   PubMedGoogle Scholar
• Ju W, Yoo BC, Kim IJ, et al.. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res. 2009;18(2–3):47–56.
   PubMed Web of Science ®Google Scholar
• L’Espérance S, Popa I, Bachvarova M, et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol. 2006;29(1):5–24.
   PubMed Web of Science ®Google Scholar
• Etemadmoghadam D, deFazio A, Beroukhim R, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Res: An Off J Am Assoc Cancer Res. 2009;15(4):1417–1427.
   PubMed Web of Science ®Google Scholar
• Helleman J, Jansen MP, Span PN, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2006;118(8):1963–1971.
   PubMed Web of Science ®Google Scholar
• Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007;25(5):517–525.
   PubMed Web of Science ®Google Scholar
• Copeland LJ, Bookman M, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol. 2003;90(2 Pt 2):S1–7.
   Google Scholar
• Bast RC Jr. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22(Suppl 8):viii5–viii15.
   PubMedGoogle Scholar